These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15782758)

  • 21. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension.
    Feldman RM
    Expert Opin Pharmacother; 2004 Apr; 5(4):909-21. PubMed ID: 15102573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension.
    Miglior S; Grunden JW; Kwok K;
    Eye (Lond); 2010 Jul; 24(7):1234-42. PubMed ID: 20019759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination.
    Akman A; Cetinkaya A; Akova YA; Ertan A
    Eye (Lond); 2005 Feb; 19(2):145-51. PubMed ID: 15184958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of prophylactic intraocular pressure-lowering medication on pain during cataract surgery.
    Ulaş F; Balbaba M; Çelebi S
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):658-62. PubMed ID: 23461283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.
    Higginbotham EJ; Diestelhorst M; Pfeiffer N; Rouland JF; Alm A
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S133-40. PubMed ID: 12204710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension.
    Pachimkul P; Yuttitham K; Thoophom P
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S81-7. PubMed ID: 21717884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the intraocular pressure-reducing effect of latanoprost as monotherapy in open-angle glaucoma.
    Mandić Z; Bojić L; Novak-Laus K; Sarić D
    Coll Antropol; 2002 Dec; 26(2):595-600. PubMed ID: 12528287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
    Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Timolol topical ophthalmic combination].
    Călugăru M; Călugăru D
    Oftalmologia; 2004; 48(1):5-14. PubMed ID: 15279411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].
    Araie M; Yamazaki Y; Sugiyama K; Kuwayama Y; Tanihara H
    Nippon Ganka Gakkai Zasshi; 2012 Oct; 116(10):955-66. PubMed ID: 23285843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of the rate of nonresponders to latanoprost therapy.
    Rossetti L; Gandolfi S; Traverso C; Montanari P; Uva M; Manni G; Carassa R; Mastropasqua L; Quaranta L; Marchini G; Ratiglia R; Orzalesi N
    J Glaucoma; 2006 Jun; 15(3):238-43. PubMed ID: 16778647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.